Supplies of Shingrix have not kept pace with demand, and the vaccine’s maker, GlaxoSmithKline, expects shipping delays and order limits to continue through 2018.
While the older shingles vaccine, Zotavax, is not in short supply, Shingrix provides up to 90 percent greater protection and last longer, so providers prefer it for their patients.
The new vaccine was approved last fall by the FDA and is recommended by the CDC.
More articles on supply chain:
Jaundice meter recalled after serious newborn injuries: 4 things to know
FDA releases 2nd draft of its software pre-certification program
FDA approves 1st glucose monitoring system with implantable sensor, monitoring app
